Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chung Hwa Chemical Industrial Works, Ltd. (1727.TW)
Taoyuan City, TW
Chung Hwa Chemical Industrial Works, Ltd., established in Taoyuan City, Taiwan, in 1956, is a global enterprise engaged in the manufacturing and distribution of various chemical products. The company's offerings encompass essential industrial chemicals such as acids, alkalis, and phosphates, which are utilized across diverse sectors including water treatment, detergent production, papermaking, textile processing, and the fabrication of printed circuit boards (PCBs). Beyond these foundational materials, Chung Hwa also develops and supplies an array of specialized chemicals. This category includes advanced compounds like reactive UV absorbers, polymer additives, sulfonated monomers, catalysts, thermal paper materials, and surface active agents, which cater to high-tech and niche applications in industries such as dyes, plastics, chemical textiles, integrated circuit (IC) wafers, display panels, and the broader electronics and optoelectronics markets. Furthermore, the company provides sophisticated electronic chemicals, prominently featuring Saint-Gobain process fluid systems crucial for etching liquid cleaning and fluid transport within electronic manufacturing facilities. Their portfolio is rounded out with solutions for water treatment and biomass chemical applications.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.45% | +19.57% | +47.81% | +118.85% | +136.16% | +141.06% | +323.94% | +151.81% | +742.74% | +713.23% | +3,950.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-5.5% Q1'26: +14.9% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-92.1% Q1'26: +660.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%-5.1% Q1'26: -28.4% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+0.1% Q1'26: +8.3% (vs Q1'25)
-
ROIC Chemicals: +3.4%+0.0% Q1'26: +4.9% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+2.4% Q1'26: -1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×4.15× Q1'26: 2.84× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
2.31B
est: 2.35B (-1.8%)
|
1.72B
est: 2.41B (-28.3%)
|
2.08B
est: 2.35B (-11.4%)
|
1.97B
est: 2.35B (-16.2%)
|
2.35B
2.35B – 2.35B
+0.0% YoY
|
2.41B
2.41B – 2.41B
+2.3% YoY
|
2.11B
2.11B – 2.11B
-12.2% YoY
|
2.54B
2.54B – 2.54B
+20.5% YoY
|
| EBITDA |
268.28M
est: 320.32M (-16.2%)
|
222.70M
est: 327.82M (-32.1%)
|
311.65M
est: 325.39M (-4.2%)
|
236.31M
est: 325.39M (-27.4%)
|
325.39M
325.39M – 325.39M
+0.0% YoY
|
333.01M
333.01M – 333.01M
+2.3% YoY
|
292.30M
292.30M – 292.30M
-12.2% YoY
|
352.25M
352.25M – 352.25M
+20.5% YoY
|
| EBIT |
72.70M
est: 83.18M (-12.6%)
|
16.30M
est: 85.13M (-80.9%)
|
77.24M
est: 76.81M (+0.6%)
|
1.01M
est: 76.81M (-98.7%)
|
76.81M
76.81M – 76.81M
+0.0% YoY
|
78.60M
78.60M – 78.60M
+2.3% YoY
|
68.99M
68.99M – 68.99M
-12.2% YoY
|
83.15M
83.15M – 83.15M
+20.5% YoY
|
| Net Income |
46.90M
est: 84.98M (-44.8%)
|
43.73M
est: 114.53M (-61.8%)
|
63.13M
est: 87.00M (-27.4%)
|
5.11M
est: 87.00M (-94.1%)
|
87.00M
87.00M – 87.00M
+0.0% YoY
|
117.26M
117.26M – 117.26M
+34.8% YoY
|
44.13M
44.13M – 44.13M
-62.4% YoY
|
158.86M
158.86M – 158.86M
+260.0% YoY
|
| SGA |
193.34M
est: 207.29M (-6.7%)
|
157.20M
est: 212.15M (-25.9%)
|
182.41M
est: 205.91M (-11.4%)
|
164.81M
est: 205.91M (-20.0%)
|
205.91M
205.91M – 205.91M
+0.0% YoY
|
210.73M
210.73M – 210.73M
+2.3% YoY
|
184.97M
184.97M – 184.97M
-12.2% YoY
|
222.91M
222.91M – 222.91M
+20.5% YoY
|
| EPS |
0.43
est: 0.69 (-37.7%)
|
0.39
est: 0.93 (-58.1%)
|
0.51
est: 0.69 (-26.1%)
|
0.04
est: 0.69 (-94.1%)
|
0.69
0.69 – 0.69
+0.0% YoY
|
0.93
0.93 – 0.93
+34.8% YoY
|
0.35
0.35 – 0.35
-62.4% YoY
|
1.26
1.26 – 1.26
+260.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 11.5K | 0.42% |
| 2 | Avantis Emerging Markets Value ETF AVES | 0.01% | 109.1K | 0.36% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 131.4K | 0.46% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ching-An Cheng | Financial Officer, Accounting Officer & Director | — | — |
| Kai En Gan | President | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1727.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
